SUMMARY OF INVENTION
Lymphoma is the most common hematological cancer in dogs. Canine diffuse large B cell lymphoma shows a relatively good response to treatment with multi-agent cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy; however, the 2-year survival rate is as low as 20%. For human B cell type lymphoma, the anti-CD20 chimeric antibody, rituximab, was developed two decades ago. The combination of rituximab and CHOP chemotherapy was highly successful in improving patient prognosis. Here we describe the anti-canine CD20 antibody generation for the treatment of canine lymphoma.
Scientists at MSK generated recombinant antibody constructs that comprise the variable regions of the heavy and light chains of canine anti-CD20 antibodies. The antibody constructs may be transduced into T-cells to produce populations of T-cells which target canine CD20-producing target/tumor cells. These antibody constructs also may be coupled to a label such as a radiolabel, or to a protein such as streptavidin, or to pro-drug converting enzymes for use in imaging or therapeutic applications.
- The investigator has done pathbreaking research on CAR T-cells, and MSK is a leader in CAR T-cell research
- Anti-CD20 antibody can be used in the delivery of imaging agents or therapeutic agents to canine or cross-reactive species derived cancers or diseases.
Lymphoma accounts for 15% to 20% of new cancer diagnoses in dogs, most commonly in middle-aged or older animals. This application relates to canine anti-CD20 antibodies and derived single chain antibody constructs which specifically bind to the canine CD20, and to the use of such constructs for targeted delivery of imaging agents or therapeutic agents to canine or cross-reactive species derived cancers or diseases.
AREAS OF APPLICATION
- Imaging agent
- Therapeutic agent
PCT/US2019/018535 Pending (Filed Aug 18, 2020)
Isabelle Riviere, PhD, Director, Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering
Eileen Flowers, Ph.D.